Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
收藏DataCite Commons2025-12-05 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012102/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus
提供机构：
Vivli
创建时间：
2025-12-05
